DPx Launched as Provider of Pharmaceutical Services, Fine Chemicals, and Proprietary Technologies
DPx Holdings is a new CDMO for the pharmaceutical and related industries, formed from a $2.65 billion transaction between JLL Partners, a private equity firm, and Royal DSM, a life-sciences and materials sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM.
Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units that is comprised of three brands focused on pharmaceutical services, fine chemicals and products, and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon, and Banner Life Sciences.
Pharmaceutical services will operate under the Patheon brand name and include the CMO capabilities, pharmaceutical product development services, as well as biosolutions and biologics businesses of DPP. In addition, fine chemicals, or the ES/IM and API businesses, will operate under the brand name DSM Fine Chemicals, while proprietary products and technologies will operate under Banner Life Sciences.
DSM Fine Chemicals will also handle complicated APIs and finished dosage forms, and Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.
DPx’s 2014 sales are expected to be about $2 billion (pro-forma). DPx has 24 locations across North America, Europe, Latin America, and Australia with more than 8000 employees.
Source: DPx Holdings